Savara  logo
Savara SVRA
$ 5.38 2.09%
report update icon

Quarterly report 2026-Q2
added 08-11-2026

Savara Balance Sheet 2025-1996 | SVRA

Brief overview of Savara 's assets and capital

The comparison uses five available annual reports from the 2021–2025 interval.

Assets increased from $176.6 million to $253.4 million, or +43.5%; CAGR of about 9.5% indicates steady balance sheet expansion.

Liability growth of +56.7% exceeded asset growth of +43.5%, increasing reliance on outside funding.

Equity funds 80.2% of assets versus 81.8% initially. This creates a conservative balance sheet structure.

Net debt moved below zero to -$3.3 million, reflecting surplus cash over debt.

Cash equals 13.1% of the balance sheet, compared with 19.3% five periods ago. This is the readily available cushion.

Retained earnings are negative at -$608.1 million. This reduces the formal capital cushion, although large shareholder returns may have contributed.

Overall picture

Savara 's financial position is more positive than negative: the funding mix is workable, although the cushion is not unlimited.

Annual Balance Sheet Savara

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996

Net Debt

-3.27 M 11.7 M -37 K -26 M -8.36 M 27.3 M -24.7 M 86.8 M 64.8 M -4.71 M -8.34 M -35.8 M -25.7 M -22.5 M -43.6 M - - - - - - - - - - - - - - -

Long Term Debt

29.9 M 26.6 M 26.3 M 26.1 M 17.3 M 25.1 M 23.1 M 24.5 M 14.8 M 2.28 M 3.73 M - - - - - - - - - - - - - - - - - - -

Long Term Debt Current

- 200 K 200 K 60 K 8.33 M - - - - - - - - - - - - - - - - - - - - - - - - -

Total Non Current Liabilities

- - - - - 25.2 M 23.6 M 36.8 M 34.3 M 3.3 M 7.16 M 3.4 M 2.61 M 2.61 M 2.61 M - - - - - - - - - - - - - - -

Total Current Liabilities

20.4 M 14.7 M 10.6 M 5.87 M 14.7 M 8.17 M 10.9 M 7.25 M 6.02 M 4.87 M 23.2 M 8.44 M 4.83 M 2.57 M 2.47 M 1.8 M - - - - - - - - - - - - - -

Total Liabilities

50.3 M 41.4 M 37.2 M 32 M 32.1 M 33.4 M 34.5 M 44.1 M 40.3 M 8.16 M 30.3 M 11.8 M 7.44 M 5.18 M 5.08 M 1.8 M - - - - - - - - - - - - - -

Deferred Revenue

- - - - - - - 250 K - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

-608 M -489 M -393 M -339 M -301 M -258 M -208 M -130 M -68.2 M -311 M -275 M -235 M -206 M -185 M -169 M - - - - - - - - - - - - - - -

Total Assets

253 M 213 M 178 M 140 M 177 M 97.7 M 136 M 152 M 160 M 17.9 M 54.2 M 70.5 M 55.2 M 47 M 61.9 M 28.5 M - - - - - - - - - - - - - -

Cash and Cash Equivalents

33.2 M 15.1 M 26.6 M 52.1 M 34 M 22.9 M 49.8 M 24.3 M 22.1 M 13.4 M 23.1 M 35.8 M 25.7 M 22.5 M 43.6 M 28 M 8.67 M - - - - - - - - - - - - -

Book Value

203 M 171 M 140 M 108 M 144 M 64.4 M 102 M 108 M 119 M 9.76 M 23.9 M 58.7 M 47.8 M 41.8 M 56.8 M 26.7 M - - - - - - - - - - - - - -

Total Shareholders Equity

203 M 171 M 140 M 108 M 144 M 64.4 M 102 M 108 M 119 M -35.9 M 23.9 M 58.7 M 47.8 M 41.8 M 56.8 M 26.7 M 6.67 M 6 M 31 M 20 M -7.83 M 12.4 M 4.12 M -853 K -638 K 14.6 M -1.23 M -525 K 382 K -273 K

All numbers in USD currency

Quarterly Balance Sheet Savara

2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

30.1 M 30.1 M 29.9 M 29.8 M 29.7 M 29.5 M 26.6 M 26.6 M 26.5 M 26.4 M 26.3 M 26.3 M 26.2 M 26.1 M 26.1 M 26 M 25.9 M 13.3 M 17.3 M 21.4 M 25.4 M 25.2 M 25.1 M 25.1 M 25.1 M 25.1 M 300 K 300 K 300 K 500 K - - - - - - - - - - - - - - 25 K 27 K - - - - - - - - - - - - - - - -

Total Liabilities

50.3 M 45.6 M 41.4 M 46.5 M 43.3 M 41.5 M 41.4 M 39.5 M 37.9 M 36.4 M 37.2 M 35.5 M 32.1 M 31.1 M 32 M 31.2 M 29.7 M 29.7 M 32.1 M 32 M 31.1 M 32.5 M 33.4 M 33.4 M 33.4 M 33.4 M 34.5 M 34.5 M 34.5 M 34.5 M 44.1 M 44.1 M 44.1 M 44.1 M 40.3 M 40.3 M 40.3 M 40.3 M 20.9 M 20.9 M 20.9 M 8.16 M 30.3 M 30.3 M 30.3 M 30.3 M 11.8 M 11.8 M 11.8 M 11.8 M 7.44 M 7.44 M 7.44 M 7.44 M 5.18 M 5.18 M 5.18 M 5.18 M 5.08 M 5.08 M 5.08 M 5.08 M

Retained Earnings

-608 M -645 M -489 M -576 M -546 M -516 M -489 M -460 M -436 M -414 M -393 M -377 M -361 M -349 M -339 M -328 M -318 M -309 M -301 M -289 M -279 M -268 M -258 M -258 M -258 M -258 M -208 M -208 M -208 M -208 M -130 M -130 M -130 M -130 M -68.2 M -68.2 M -68.2 M -68.2 M -38.4 M -38.4 M -38.4 M -311 M -275 M -275 M -275 M -275 M -235 M -235 M -235 M -235 M -206 M -206 M -206 M - - - - - - - - -

Total Assets

253 M 222 M 213 M 141 M 164 M 189 M 213 M 239 M 140 M 158 M 178 M 182 M 120 M 129 M 140 M 148 M 157 M 166 M 177 M 187 M 196 M 208 M 97.7 M 97.7 M 97.7 M 97.7 M 136 M 136 M 136 M 136 M 152 M 152 M 152 M 152 M 160 M 160 M 160 M 160 M 28.9 M 28.9 M 28.9 M 17.9 M 54.2 M 54.2 M 54.2 M 54.2 M 70.5 M 70.5 M 70.5 M 70.5 M 55.2 M 55.2 M 55.2 M 55.2 M 47 M 47 M 47 M 47 M 61.9 M 61.9 M 61.9 M 61.9 M

Cash and Cash Equivalents

33.2 M 38.8 M 15.1 M 16.3 M 17.4 M 19.6 M 15.1 M 21.4 M 23.9 M 16.8 M 26.6 M 27.7 M 22.7 M 34 M 52.1 M 120 M 95.2 M 79.2 M 34 M 44.7 M 40.7 M 56 M 22.9 M 22.9 M 22.9 M 22.9 M 49.8 M 49.8 M 49.8 M 49.8 M 24.3 M 24.3 M 24.3 M 24.3 M 22.1 M 22.1 M 22.1 M 22.1 M 13.4 M 13.4 M 13.4 M 8.54 M 16.7 M 23.1 M 23.1 M 23.1 M 12.7 M 35.8 M 35.8 M 35.8 M 25.7 M 25.7 M 25.7 M 25.7 M 22.5 M 22.5 M 22.5 M 22.5 M 43.6 M 43.6 M 43.6 M 43.6 M

Book Value

203 M 176 M 171 M 94.4 M 120 M 148 M 171 M 199 M 102 M 122 M 140 M 147 M 87.7 M 98.3 M 108 M 117 M 127 M 136 M 144 M 155 M 165 M 175 M 64.4 M 64.4 M 64.4 M 64.4 M 102 M 102 M 102 M 102 M 108 M 108 M 108 M 108 M 119 M 119 M 119 M 119 M 7.99 M 7.99 M 7.99 M 9.76 M 23.9 M 23.9 M 23.9 M 23.9 M 58.7 M 58.7 M 58.7 M 58.7 M 47.8 M 47.8 M 47.8 M 47.8 M 41.8 M 41.8 M 41.8 M 41.8 M 56.8 M 56.8 M 56.8 M 56.8 M

Total Shareholders Equity

-750 K 176 M -271 K 94.4 M 120 M 148 M 171 M 199 M 102 M 122 M 140 M 147 M 87.7 M 98.3 M 108 M 117 M 127 M 136 M 144 M 155 M 165 M 175 M 64.4 M 64.4 M 64.4 M 64.4 M 102 M 102 M 102 M 102 M 108 M 108 M 108 M 108 M 119 M 119 M 119 M 119 M -35.9 M -35.9 M -35.9 M 9.76 M -27.3 M 23.9 M 23.9 M 23.9 M -18.3 M 58.7 M 58.7 M 58.7 M 47.8 M 47.8 M 47.8 M 47.8 M 41.8 M 41.8 M 41.8 M 41.8 M 56.8 M 56.8 M 56.8 M 56.8 M

All numbers in USD currency

Balance Sheet is a fundamental financial report of Savara , providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
Celsion Corporation Celsion Corporation
CLSN
- -6.63 % $ 13.9 M usaUSA
FSD Pharma FSD Pharma
HUGE
- 5743.5 % $ 69.7 M canadaCanada
Qilian International Holding Group Limited Qilian International Holding Group Limited
QLI
- -6.08 % $ 184 M chinaChina
Happiness Biotech Group Limited Happiness Biotech Group Limited
HAPP
- 1.35 % $ 17.8 M chinaChina
Synthetic Biologics Synthetic Biologics
SYN
- 1.32 % $ 16.2 M usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
- - $ 2.02 B usaUSA
BioXcel Therapeutics BioXcel Therapeutics
BTAI
$ 1.19 5.31 % $ 14.5 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 4.37 0.23 % $ 958 M britainBritain
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
BeyondSpring BeyondSpring
BYSI
$ 0.84 34.27 % $ 34.5 M usaUSA
Corner Growth Acquisition Corp. Corner Growth Acquisition Corp.
COOL
- -0.89 % $ 114 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Cerus Corporation Cerus Corporation
CERS
$ 2.98 4.93 % $ 568 M usaUSA
Compugen Ltd. Compugen Ltd.
CGEN
$ 2.41 4.17 % $ 225 M israelIsrael
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
BiondVax Pharmaceuticals Ltd. BiondVax Pharmaceuticals Ltd.
BVXV
- 0.74 % $ 768 M israelIsrael
Abcam plc Abcam plc
ABCM
- - $ 4.9 B britainBritain
Завод ДИОД Завод ДИОД
DIOD
- - - russiaRussia
Galera Therapeutics Galera Therapeutics
GRTX
- -32.59 % $ 7.61 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Hepion Pharmaceuticals Hepion Pharmaceuticals
HEPA
- -18.79 % $ 39.3 K usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Champions Oncology Champions Oncology
CSBR
$ 5.1 2.63 % $ 70.5 M usaUSA
Affimed N.V. Affimed N.V.
AFMD
- -34.95 % $ 21.5 M germanyGermany
AnPac Bio-Medical Science Co., Ltd. AnPac Bio-Medical Science Co., Ltd.
ANPC
- -1.58 % $ 28.1 M chinaChina
Celyad Oncology SA Celyad Oncology SA
CYAD
- - $ 12.5 M belgiumBelgium
Adial Pharmaceuticals Adial Pharmaceuticals
ADIL
$ 3.98 1.86 % $ 2.66 M usaUSA
Generation Bio Co. Generation Bio Co.
GBIO
- - $ 344 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
AnaptysBio AnaptysBio
ANAB
$ 58.47 4.37 % $ 1.68 B usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
$ 21.5 1.56 % $ 308 M usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
- -4.36 % $ 27 M usaUSA
Gracell Biotechnologies Gracell Biotechnologies
GRCL
- - $ 3.37 B chinaChina
Aurinia Pharmaceuticals Aurinia Pharmaceuticals
AUPH
$ 15.47 1.91 % $ 2.08 B canadaCanada
GlycoMimetics GlycoMimetics
GLYC
- 9357.83 % $ 1.01 B usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Bicycle Therapeutics plc Bicycle Therapeutics plc
BCYC
$ 3.9 0.24 % $ 270 M britainBritain
Beam Therapeutics Beam Therapeutics
BEAM
$ 26.75 0.91 % $ 2.65 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 67.36 0.99 % $ 12.9 B usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada